Serotonin (5-hydroxytryptamine or 5-HT) modulates the activity of the central nervous system as well as processes throughout the body ranging from cardiovascular function to digestion, body temperature, endocrinology and reproduction 1 . Discovered in the late 1940s as a signalling molecule, serotonin increases vasoconstriction after blood clotting, that is, serum-tone 2 . In the brain, the raphe nuclei synthesize serotonin from tryptophan, and distribute serotonin via long projections that reach nearly every major brain region. Serotonin is released into the synaptic cleft between neurons, where it diffuses to activate serotonin receptors, a group of G-protein-coupled receptors and ligand-gated ion channels that participate in both excitatory and inhibitory neurotransmission and modulate the release of many neurotransmitters and hormones. Thus, serotonergic signalling influences neurological processes including sleep, mood, cognition, pain, hunger and aggression behaviours. The discovery that serotonin reuptake into nerve terminals is inhibited by the tricyclic antidepressant imipramine in a manner similar to norepinephrine (also known as noradrenaline) reuptake provided an initial clue that transport occurs by a related reuptake system 3-5 . Prozac was introduced as one of the first selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression and, subsequently, the serotonin transporter gene (SERT, also known as SLC6A4) was cloned and proven to be the target of SSRIs 6,7 .
Architecture of human SERT
The structure of human SERT bound to (S)-citalopram or paroxetine exhibits an outward-open conformation with the antidepressant drug bound to the central site, halfway across the membrane and wedged into a cavity made up of residues from TM1, TM3, TM6, TM8 and TM10 (Fig. 1b, c) . A second (S)-citalopram molecule was found in the allosteric site, within the extracellular vestibule of the (S)-citalopram cocrystal structure, approximately 13 Å from the central site. Akin to dDAT and LeuT, SERT has 12 transmembrane-spanning helices with TM1-TM5 and TM6-TM10 related by a pseudo-two-fold axis 14, 16, 20, 21 (Extended Data Fig. 1 ). The ts2 and ts3 transporters superimpose well (Extended Data Table 3 ), demonstrating that the additional mutation of the ts3 construct does not substantially perturb the functionally active ts2 transporter structure (Extended Data Fig. 2a ). TM1 and TM6 adopt short regions of non-helical conformation as they skirt the central ligand site and contribute residues that bind inhibitors as well as coordinate Na + and Cl − ions. The conformations of TM1 and TM6 are incompatible with the formation of an occluded state, suggesting that the antidepressant molecules have locked the transporter in an outward-open conformation, similar to the inhibitor-bound outward-open conformations of dDAT and LeuT 14, 16, 19, 21, 26 (Extended  Data Table 3 ).
The extracellular surface of SERT is largely composed of extra cellular loop (EL) 2, EL4 and EL6, with EL2 'combed-over' the extracellular surface and providing 3,376 Å 2 of solvent-accessible surface area. A conserved disulfide bridge is formed between Cys200 and Cys209 in EL2 (ref. 27) . EL2 is predicted to contain two N-linked glycosylation sites, Asn208 and Asn217 (ref. 28) , and electron density for a N-acetylglucosamine moiety was found linked to Asn208; weak density was also found near Asn217. Similar to dDAT, the intracellular surface of the transporter is capped by intracellular loop (IL) 1, IL5 and the carboxy-terminal helix. Unlike LeuT, yet reminiscent of dDAT, TM12 has a pronounced kink halfway across the membrane. There is a cholesterol hemisuccinate (CHS) molecule bound near TM12a.
The crystal lattice packing between two SERT molecules occurs at the kink in TM12, which also overlaps with a two-fold axis of crystallographic symmetry (Extended Data Fig. 2c ), thus generating an apparent SERT 'dimer' . Experiments suggest that SERT is an oligomer in the membrane 29 . However, in detergent SERT is a monomer and we suggest that the SERT 'dimer' observed in this crystal form is unlikely to exist in a membrane bilayer because the predicted membrane-spanning regions of each protomer are not aligned with one another. Because the electron density for the Fab constant domain was poor, we also solved the structure of the Fab at 1.6 Å resolution to facilitate model building and refinement (Extended Data Fig. 2f and Extended Data Table 1 ). The Fab binds to a large extracellular surface consisting of EL2 and EL4 in a symmetry-related SERT, and this interface is further stabilized by interactions of EL2-EL2 and Fab-EL2 in the asymmetric unit (Extended Data Fig. 2d, e) .
The structure of SERT shows that amino acid changes due to single nucleotide polymorphisms and mutations associated with psychiatric disorders are distributed throughout the structure (Extended Data Fig. 2b ). Interestingly, most of the altered residues face solvent or lipid 12 , thus rendering their effect on SERT structure and function obscure. Pro339Leu, however, is located in the non-helical region of TM6 neighbouring the ligand-binding site and, not surprisingly, this variant exhibits diminished transport activity. By contrast, other disease-associated mutations and polymorphisms, including mutations at Ile425 in TM8, Lys201Asn in EL2 (ref. 30 ) and Ser293Phe and Leu362Met in TM5 and TM7 enhance serotonin transport, respectively. Another class of mutations, Phe465Leu in TM9 and Leu550Val in TM11, probably destabilize the transporter or, as in the case of the Lys605Asn substitution in the C-terminal helix, render the transporter insensitive to protein kinase G regulation. With the establishment of SERT structural analysis, together with SERT expression and purification, we can now determine more precisely how these mutations alter the structure and activity of SERT.
Antidepressant bound at the central site
To probe the capacity of the ts2 and ts3 SERT constructs to bind antidepressants, we carried out binding studies using [ 3 H](R/S)-citalopram and [ 3 H]paroxetine ( Fig. 2a, b ). (R/S)-citalopram binds with dissociation constant (K d ) values of 2.1 ± 0.1, 1.9 ± 0.3 and 2.9 ± 0.5 nM to the wild-type, ts2 and ts3 variants 31 , whereas paroxetine exhibits K d values of 0.08 ± 0.03, 0.17 ± 0.03 and 0.10 ± 0.02 nM for wild-type, ts2 and ts3 constructs 31 , respectively.
We next investigated the structure of the antidepressant binding site in the paroxetine and (S)-citalopram complexes by dividing the site into subsites A, B and C 15 ( Fig. 2c-e ). Multi-crystal averaging of three (S)-citalopram data sets resulted in electron density maps that supported placement of the cyanophtalane group in subsite C and the fluorophenyl in subsite B, in agreement with detailed mutagenesis and ligand-binding studies 32 (Fig. 2c ). Nevertheless, because of the limited resolution of the diffraction data, we wanted to ensure that we had positioned (S)-citalopram correctly. To do this, we crystallized SERT with a bromine derivative of citalopram, (R/S)-1-[3-(dimethylamino) propyl]-1-(4-bromophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, in which the 4-fluoro group is replaced with a bromine atom (Br-citalopram). Upon analysis of the resulting anomalous difference Fourier map, we found a strong anomalous signal (>9σ) in subsite B, corresponding to the predicted position of the bromine atom of the Br-citalopram derivative and, by extension, the fluorine atom of (S)-citalopram ( Fig. 2d ). These data are consistent with the fluorophenyl group of (S)-citalopram occupying subsite B. The nontherapeutic R-enantiomer of citalopram has markedly weaker affinity for SERT, perhaps because the aromatic substituents swap subsites, relative to the S-enantiomer 33 . Inspection of F o − F c omit electron density maps allowed placement of paroxetine in the central binding site with the benzodioxol and fluorophenyl groups in subsites B and C ( Fig. 2e ). It is noteworthy that the chemically equivalent fluorophenyl groups of (S)-citalopram and paroxetine are positioned in different subsites.
The amine groups of (S)-citalopram and paroxetine occupy subsite A and interact with the carboxylate of the conserved Asp98 (ref. 34 ) at a distance of 4.1 and 3.1 Å ( Fig. 2f , g), perhaps explaining, in part, why paroxetine has a higher affinity for SERT in comparison to (S)-citalopram. Tyr95 localizes 4.2 and 5.3 Å beneath the amine groups of (S)-citalopram and paroxetine, forming a cation-π interaction crucial for citalopram and mazindol potency 35 . Tyr95 may also form a hydrogen bond with the oxygen of (S)-citalopram. Ser336 partners in an interaction network with ligands and ions by participating in Na + and Cl − coordination, ions that are essential for ligand binding and substrate transport [36] [37] [38] .
Subsite B is particularly important for high-affinity antidepressant interaction as evidenced by mutations that influence citalopram binding 32, 39 . Tyr176 engages in hydrophobic interactions with the fluorophenyl and benzodioxol groups of (S)-citalopram and paroxetine while also hydrogen bonding with Asp98. Ile172 and Phe341 define a non-polar ridge that cradles the hydrophobic groups of the drugs, and inhibitor binding is weakened upon mutation of these residues 32, 40 . Phe341 in SERT, which is equivalent to Phe325 in dDAT, has swung 'downward' by nearly 40° and forms an aromatic interaction with the 'face' of the cyanophtalane of (S)-citalopram and with the 'edge' of the fluorophenyl group of paroxetine (Extended Data Fig. 3a, b ). Ser439, Leu443, Ala169 and Ala173 define a cavity that is more hydrophobic in SERT in comparison to the equivalent cavity in dDAT, and into which the fluorine and dioxol ring groups of (S)-citalopram and paroxetine are inserted (Extended Data Fig. 3c ). The fluorophenyl group of (S)-citalopram is positioned 1.5 Å deeper into this space compared with the benzodioxol of paroxetine (Extended Data Fig. 3b ).
The fluorophenyl group of paroxetine stacks parallel to the ring of Phe335 in subsite C. By contrast, for (S)-citalopram, the cyanophtalane forms an edge-to-face aromatic interaction. Phe335 defines the extracellular gate, and TM1 and TM6 are markedly different when comparing SERT to dDAT bound to a substrate analogue 19 (Extended  Data Table 3) , showing that (S)-citalopram and paroxetine 'prop' TM6a in an outward-open conformation. Val501 and Thr497 form a mixed non-polar/polar surface into which the fluoro and cyano groups of paroxetine and (S)-citalopram are found. In the case of (S)-citalopram, the cyano group is inserted 2.1 Å further into subsite C, and the hydroxyl group of Thr497 is positioned 1.7 Å away from its position in the paroxetine state (Extended Data Fig. 3b ). In accord with the SERTcitalopram X-ray structure, a modest increase in citalopram affinity is observed for the Thr497Ala mutant 39 , which would allow additional space for the cyano group.
Ion-binding sites
Na + and Cl − ions, which are essential for substrate transport and SSRI binding 41 , could be identified with electron densities >3σ in F o − F c 'omit' maps (Extended Data Fig. 4 ), at positions similar to those found in dDAT (Extended Data Table 4 ). The Na1 site is made up of residues contributed from TM1, TM6 and TM7 and the ion is coordinated by Ala96, Asn101, Ser336 and Asn368. Whereas Na1 is coordinated, in part, by a water molecule in dDAT, which in turn is hydrogen-bonded to Asp46, in SERT there is not sufficient density to place water at a similar position. The chloride ion is coordinated by Tyr121, Gln332, Ser336 and Ser372 from TM2, TM6 and TM7 with a mean coordination distance of 3.1 Å. Strong density for Na2 could be seen in the (S)-citalopram structure with the ion coordinated by Gly94, Val97, Leu434, Asp437 and Ser438 from TM1 and TM8. Placing ions in the omit densities led to a loss in F o − F c density and the B-values of the ions match the values of surrounding residues. The mean coordination distance (2.4 Å) corresponds to known coordinate distances for sodium 42 . Only weak density for Na2 could be seen in the paroxetine structure, while in the (S)-citalopram complex the density for Cl − was weak, perhaps reflecting the overall weaker density in these regions rather than a difference in occupancy. 
Extracellular and intracellular gates
The SERT-SSRI complexes adopt an outward-open conformation that exposes the cone-shaped extracellular vestibule to aqueous solution, providing a pathway for substrates, inhibitors and ions to reach the central binding site, approximately halfway across the membrane bilayer. As in LeuT, the extracellular vestibule contains residues that form the extracellular gate, and is lined by TM1b and TM6a, as well as by extracellular regions of TM3, TM8, TM10 and TM11, together with EL6 and the 'tip' of EL4. The mixed polar and non-polar character of the extracellular vestibule provides low affinity binding sites for small molecules, similar to LeuT, and in SERT we find electron density attributed to a second (S)-citalopram molecule in the (S)-citalopram cocrystal structure and a maltose detergent head group in the paroxetine complex within the extracellular vestibule 14, [43] [44] [45] (Fig. 3a, b) . At the base of the vestibule is the extracellular gate, and near the cytoplasmic face of SERT is the intracellular gate (Extended Data Fig. 5a, b ). In SERT, Tyr176 and Phe335 define the lower portion of the extracellular gate and are separated by a distance of 10 Å, thus providing open access to the extracellular vestibule. In comparison to the extracellular gate of dDAT, the equivalent region in SERT exhibits notable structural changes: Tyr176 and Asp98 are separated by 4.0 Å and TM10 is closer to TM1b, bringing Glu494 and Arg104 within 4.8 Å, and thus the central site can only be accessed through the extracellular vestibule. The intracellular gate of SERT is closed, similar to the outward facing conformations of dDAT and LeuT, thus precluding direct access from the central ligand binding site to the intracellular solution ( Fig. 3 and Extended Data Fig. 5b ).
Allosteric site
To determine whether the off-rate of inhibitor from the central site is modulated by a ligand binding to an allosteric site in the ts3 construct, we measured the dissociation of [ 3 H](R/S)-citalopram from the central site in the presence of saturating concentrations of cold (S)-citalopram. As shown in previous studies, micromolar concentrations of (S)-citalopram, serotonin and other ligands slow dissociation from the central site 10, 11 . For ts3, 100 μM (S)-citalopram decreased the first-order rate of [ 3 H](R/S)-citalopram dissociation by nearly tenfold compared to buffer alone (0.0032 ± 0.0007 versus 0.025 ± 0.002 min −1 ) ( Fig. 4a) , with the wild-type and ts2 transporters exhibiting similar effects (wild-type: 0.004 ± 0.001 versus 0.035 ± 0.004 min −1 ;ts2: 0.0028 ± 0.001 versus 0.08 ± 0.03 min −1 ), thus showing that allosteric modulation of ligand unbinding is intact in the ts2 and t3 constructs.
The allosteric binding site of (S)-citalopram is defined by residues in TM1b, TM6a, TM10 and TM11, and in EL4 and EL6 ( Fig. 4b and Extended Data Fig. 5c ) with prominent electron density (>5σ in F o − F c omit maps) present in this region for crystals soaked with (S)-citalopram. Interestingly, mutagenesis of residues proximal to the allosteric site has been reported to severely alter allosteric potency 46 yet the physiological role of this site is not well established 47 . Residues of the extracellular gate, Glu494 and Arg104, are located 4.1 and 4.8 Å from the aminopropyl group, while Asp328 is 6.8 Å away. Arg104 is also located 3.6 Å from the cyanophtalane ring and probably participates in a cation-π interaction, while the cyano group of the phtalane ring is 3.1 Å from the side-chain amide of Gln332. Ala331 forms a non-polar groove into which the ring system of (S)-citalopram is buttressed. Phe556 is 3.5 Å from the fluorophenyl group and participates in aromatic interactions while a proline repeat (Pro560-Pro561) in EL6 demarcates the upper portion of the allosteric site, 6.6 Å from the fluorophenyl entity.
To confirm the identity of the ligand bound to the allosteric site, we soaked crystals with Br-citalopram. A strong anomalous signal (>5σ) corresponding to bromine was detected in anomalous difference electron density maps, confirming the position and pose of citalopram in the allosteric site ( Fig. 4c ). However, there was not sufficient electron density to place the aminopropyl group of Br-citalopram and thus we excluded it from the structure.
In the paroxetine complex, we found electron density for a putative maltose entity, presumably derived from a detergent molecule (Extended Data Fig. 5d ) occupying a position in the extracellular vestibule that partially overlaps with (S)-citalopram bound in the allosteric site ( Fig. 4d ). Upon analysis of the allosteric site of the (S)-citalopram and paroxetine complexes, we note considerable plasticity, presumably owing to the nature of the bound molecule. Relative to the (S)-citalopram-bound allosteric site, in the paroxetine structure Phe556 moves 'downwards' towards TM6a, to a position underneath the maltose. In addition, Arg104 moves 2 Å further into the allosteric site, while EL6 also moves 1.3 Å towards TM10, with the largest change occurring at Pro561. The malleability of the allosteric site opens the possibility that, depending on the shape and size of the allosteric ligand, occupancy of the allosteric site might not necessarily abrogate transport activity. Indeed, it is conceivable that there could be a spectrum of small molecules that range from inhibiting to enhancing transport activity. Comparison of the allosteric site of SERT with the equivalent region of dDAT shows how the SERT site is distinct from that of dDAT, even though SERT and dDAT are highly similar in structure within their cores around the central ligand binding site (TM1-TM8; Extended Data Table 3 ). Indeed, there are marked differences between SERT and dDAT for TM9-TM12 and the extracellular loops ( Fig. 5a and Extended Data Table 3 ). EL2, centrally positioned within the extracellular domain, is longer in SERT than in dDAT and participates in extensive interactions with EL4 and EL6, which together sculpt a portion of the allosteric site (Fig. 5b, c) . Moreover, when comparing the amino acid sequences of human SERT, DAT and NET, EL6 displays one of the highest regions of diversity, consistent with the observation that allosteric ligands of SERT do not modulate DAT or NET. Furthermore, EL6 adopts a unique conformation not observed in dDAT because it extends more than 4 Å further towards EL2.
The conformation of TM9-TM12 also defines the allosteric site (Fig. 5d ). Comparisons between dDAT and SERT illustrate that in SERT TM9 is shifted towards TM12, perhaps coordinated by contacts via EL5 and TM10, the latter of which contains a short stretch of π-helix near Glu494, a key residue of the extracellular gate. In SERT, TM11 extends further into the putative membrane environment in comparison to dDAT, thus providing a larger cavity for allosteric ligands, while TM12a splays inward to buttress TM10 and TM11. Finally, interaction of cholesterol, which is known to modulate transport and ligand binding 48 together with other lipid molecules, may reinforce the conformation of TM12. Indeed, in SERT a CHS molecule stacks against Trp573 in a groove formed by Leu577, Ile576 and Ala580 and the extracellular portion of TM12a (Extended Data Fig. 6b ), along with a presumed alkyl chain of a detergent molecule bound in a cavity composed of residues from TM10 and TM12a (Extended Data Fig. 6c ).
Intracellular surface and C-terminal hinge
IL5 and the intracellular half of TM11 are highly similar to dDAT, while IL4 is partially unwound due to the insertion of Trp458 (Fig. 5d ). The C terminus of SERT mimics dDAT with a similar hinge and helix region (Fig. 5e ). Glu615 is thought to form a salt bridge with Arg152 in IL1 (ref. 49 ), but no side-chain density is present, which makes assignment of C-terminal register not possible. We propose that the disorder of the C terminus is due to dynamic properties, perhaps related to its importance in trafficking 50 .
Conclusion
The SERT-SSRI complexes capture the transporter in an inhibitorbound, outward-open conformation, illustrating how the bulky ligands lodge in the central binding site, preventing substrate binding and transporter isomerization to occluded and inward-open conformations. Extensive interactions throughout the central binding site explain, in large part, the selectivity of SSRIs. The allosteric site is poised 'above' the central site, within the 'walls' of the extracellular vestibule, directly obstructing ligand egress from the central site, thus explaining how allosteric ligands slow the off-rate of inhibitors bound to the central site ( Fig. 6 ). Taken together, the structures of the human serotonin transporter shed fresh insight into antidepressant recognition and the molecular basis for allosteric modulation of inhibitor binding and of transporter activity, thus providing a platform to design small molecules targeting the central and allosteric binding sites.
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METHODS
No statistical methods were used to predetermine sample size. Protein constructs. The cDNA encoding the human wild-type SERT 22 was cloned into the BacMam vector 25 with a C-terminal GFP tag. For crystallization studies, the ts3 variant contained thermostabilizing mutations Y110A, I291A, T439S and mutation of surface-exposed cysteines C554A, C580A and C622A, and was fused to a C-terminal GFP followed by twin Strep [ TrpSerHisProGlnPheGluLys(Gly GlyGlySer) 2 GlyGlySerAlaTrpSerHisProGlnPheGluLys], and His10 purification tags. The His10 tag was used in thermostability studies to capture SERT on copper scintillation beads 23 while the twin Strep tag was used for large-scale purification. Thrombin cleavage sites (LeuValProArgGlySer) were introduced in the N and C terminus after residues Gln76 and Thr618. The ts2 construct is identical to ts3 except that ts2 does not have the Y110A mutation. To raise the 8B6 antibody, residues 73-616 of wild-type SERT were cloned into BacMam with a C-terminal StrepII tag (TrpSerHisProGlnPheGluLys) and without GFP. Anti-human SERT antibody discovery and Fab expression. The 8B6 monoclonal antibody against SERT was raised by D. Cawley. StrepII-tagged SERT was purified by Strep Tactin affinity chromatography as described subsequently in DDM with 1 μM paroxetine. Liposomes containing asolectin: cholesterol:lipid A:brain polar lipid (60:17:3:20) were prepared in TBS (20 mM Tris, pH 8, 100 mM NaCl) at a concentration of 40 mg ml −1 by extrusion through 200-nm filters. Liposomes were saturated with 5 mM n-dodecyl-β-d-maltoside (DDM) and purified SERT was added to the detergent:lipid mixture. DDM was removed by three successive additions of 80 mg ml −1 biobeads. For the first two additions, the biobeads were incubated for 2 h; the final incubation was overnight. Paroxetine (10 μM) was added to the proteoliposomes after reconstitution. SERT-knockout mice were purchased from the Jackson Laboratory (mouse stain: 008355) and immunized with ~30 μg of reconstituted SERT. Hybridoma cell lines were generated as described 51 and screened by fluorescence-detection size-exclusion chromatography (FSEC) 24 and western blotting to select antibodies which recognize tertiary epitopes. The 8B6 monoclonal antibody was purified from hybridoma supernatants using 4-mercapto-ethyl-pyridine resin. Fab was purified from papain digested monoclonal antibody by cation exchange chromatography and was stored in 20 mM Tris, pH 8, 150 mM NaCl and 10% glycerol.
The sequences of the 8B6 Fab light and heavy chain genes were determined by standard techniques. The genes of the 8B6 Fab were cloned into a bicistronic insect cell expression vector, including a GP67 signal peptide. A thrombin cleavage site and 8His tag were fused to the C terminus of residues 1-235 of the heavy chain. The 8B6 Fab was purified from Sf9 supernatant by metal ion affinity chromatography followed by cation exchange chromatography. Transporter expression and purification. The human SERT constructs were expressed as C-terminal GFP fusions using baculovirus-mediated transduction of mammalian HEK293S GnTI − cells, as previously described 25, 52 . Cells were subsequently solubilized in 50 mM Tris, pH 8, 150 mM NaCl containing 20 mM DDM, 2.5 mM CHS, 0.5 mM dithiothreitol (DTT) in the presence of 1 μM inhibitor (paroxetine, (S)-citalopram, or Br-citalopram). The lysate was passed over 10 ml of Strep Tactin resin, washed with 18 column volumes of 1 mM DDM, 0.2 mM CHS, 5% glycerol, 25 μM lipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol at a molar ratio of 1:1:1), and 1 μM ligand in TBS. SERT was eluted in the same buffer containing 5 mM desthiobiotin. The N and C termini containing GFP and purification tags were removed by thrombin digestion and N-linked sugars were truncated using EndoH. SERT was mixed with recombinant 8B6 Fab at a 1:1.2 molar ratio. In the case of Br-citalopram complexed at the central site, Fab purified from hybridoma cells was used. The resulting complexes were further purified by size-exclusion chromatography in TBS supplemented with 40 mM n-octyl β-d-maltoside, 0.5 mM CHS, 5% glycerol, 25 μM lipid, and 1 μM inhibitor. The purified SERT-8B6 complex was concentrated to 2 mg ml −1 and the transporter solution was spiked with 10 μM inhibitor and 1 μM 8B6 Fab immediately before crystallization. Crystallization. The SERT-Fab complex and Fab crystals were grown by hanging drop vapour diffusion. For the ts3-Fab complex, crystals appeared after several days under conditions with a reservoir solution composed of 100 mM Tris, pH 8.5, 25-125 mM KCl, 32.5-34% PEG 400, and 0.5% 6-aminohexanoic acid with either paroxetine or (S)-citalopram at ratio of 2 μl protein to 1 μl of reservoir solution. Crystals of ts3-Fab complex with Br-citalopram bound to the central site were grown with a reservoir solution composed of 100 mM Tris, pH 8.5, 125 mM NaCl, 125 mM MgCl 2 and 33.4% PEG 400. 'Soaked' SERT-Fab crystals were prepared by addition of 5 mM ligand ((S)-citalopram or Br-citalopram) overnight to the crystals as indicated. For the ts2-Fab complex, crystals were grown using a reservoir solution containing 100 mM Tris, pH 8, 250 mM LiCl and 34.7% PEG 400 with paroxetine. All SERT-Fab crystals were grown at 4 °C, reaching full size after 14 days, and were directly flash-frozen in liquid nitrogen before X-ray diffraction data collection. The 8B6 Fab from hybridoma cells was crystallized in 100 mM HEPES, pH 7.5, 300 mM NH 4 H 2 PO 4 and 22.5% pure PEG (0.3-0.8 kDa PEG, Microlytic) at 4 °C. Fab crystals were cryoprotected with 25% ethylene glycol before flash cooling in liquid nitrogen. Data collection and structure refinement. X-ray diffraction data sets were collected at the Advanced Photon Source (Argonne National Laboratory, beamline 24-IDC and 24-IDE) and at the Advanced Light Source (Lawrence Berkeley National Laboratory, beamline 5.0.2). X-ray data was processed using XDS 53 . Molecular replacement was carried out to solve the 8B6 structure using the constant and variable domains of a preexisting Fab structure (PDB code 4LQF) as independent search models, followed by automated and manual model building and refinement using Phaser, Coot, Phenix AutoBuild and Phenix Refine [54] [55] [56] . The SERT-Fab data were processed using the microdiffraction assembly method 57 where indicated. The SERT structure was solved by molecular replacement using a multi-model search in Phaser with a homology model built using the dDAT structure (PDB code 4M48) and Modeller 58 and the constant and variable domains of the 8B6 Fab structure. Several rounds of refinement and manual model building were carried out using Phenix and Coot, respectively, until the models were refined to acceptable R-factors and stereochemistry. Radioligand binding and uptake assays. Ligand binding experiments were carried out by adding HEK293 membranes containing SERT to a final concentration of 2 nM in 1 ml of TBS with either [ 3 H]paroxetine 0.01-10 nM or [ 3 H](R/S)-citalopram 0.01-20 nM. Reactions were rotated at room temperature for 4 h followed by filtering through a glass microfibre filter prewet with 0.4% polyethylenimine in TBS. Membranes were washed three times with 4 ml of TBS followed by liquid scintillation counting. Data was fit to a single-site binding curve accounting for ligand depletion. For dissociation experiments, 20 nM SERT in membranes was mixed with 40 nM [ 3 H](R/S)-citalopram in 10 μl; samples were diluted to 1 ml in TBS with 100 μM (S)-citalopram, or without ligand, followed by filtering. For uptake assays, ~1 × 10 5 HEK293 cells in 96-well Cytostar T plates were transfected with 0.2 μg of plasmid with Polyjet. After 24-36 h, cells were washed with 25 mM HEPES-Tris, pH 7.0, 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1 mM ascorbic acid and 5 mM glucose. For a control, 10 μM paroxetine was added. [ 14 C]5-hydroxytryptamine at concentrations of 0.02-40.0 μM was added and uptake was followed using a MicroBeta scintillation counter. Data were fit to a Michaelis-Menten equation.
